|
1.
|
Steinman RM: The dendritic cell system and
its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar
|
|
3.
|
Fong L and Engleman EG: Dendritic cells in
cancer immunotherapy. Annu Rev Immunol. 18:245–273. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Banchereau J, Briere F, Caux C, et al:
Immunobiology of dendritic cells. Annu Rev Immunol. 18:767–811.
2000. View Article : Google Scholar
|
|
5.
|
Higano CS, Schellhammer PF, Small EJ, et
al: Integrated data from 2 randomized, double-blind,
placebo-controlled, phase 3 trials of active cellular immunotherapy
with sipuleucel-T in advanced prostate cancer. Cancer.
115:3670–3679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Gliboa E: DC-based cancer vaccines. J Clin
Invest. 117:1195–1203. 2007. View
Article : Google Scholar
|
|
7.
|
Ballestrero A, Boy D, Moran E, Cirmena G,
Brossart P and Nenicioni A: Immunotherapy with dendritic cells for
cancer. Adv Drug Deliv Rev. 60:173–183. 2008. View Article : Google Scholar
|
|
8.
|
Oshita C, Takikawa M, Kume A, et al:
Dendritic cell-based vaccination in metastatic melanoma patients:
Phase II clinical trial. Oncol Rep. 28:1131–1138. 2012.PubMed/NCBI
|
|
9.
|
Takeshima T, Chamoto K, Wakita D, et al:
Local radiation therapy inhibits tumor growth through the
generation of tumor-specific CTL: its potentiation by combination
with Th1 cell therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ghiringhelli F, Menard C, Puig PE, et al:
Metronomic cyclophosphamide regimen selectively depletes
CD4+CD25+regulatory T cells and restores T
and NK effector functions in end stage cancer patients. Cancer
Immunol Immunother. 56:641–668. 2007.PubMed/NCBI
|
|
11.
|
Ko HJ, Kim YJ, Kim YS, et al: A
combination of chemoimmunotherapies can efficiently break
self-tolerance and induce antitumor immunity in a tolerogenic
murine tumor model. Cancer Res. 67:7477–7486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Okamoto M, Kasetani H, Kaji R, et al:
cis-Diamminedichloroplatinum and 5-fluorouracil are potent
inducers of the cytokines and natural killer cell activity in vivo
and in vitro. Cancer Immunol Immunother. 47:233–239. 1998.
View Article : Google Scholar
|
|
13.
|
Okamoto M, Ohe G, Oshikawa T, et al:
Induction of cytokines and killer cell activities by cisplatin and
5-fluorouracil in head and neck cancer patients. Anticancer Drugs.
11:165–173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ahmed SU, Okamoto M, Oshikawa T, et al:
Anti-tumor effect of an intratumoral administration of dendritic
cells in combination with TS-1, an oral fluoropyrimidine
anti-cancer drug, and OK-432, a streptococcal immunopotentiator:
involvement of toll-like receptor 4. J Immunother. 27:432–441.
2004. View Article : Google Scholar
|
|
15.
|
Kimura Y, Tsukada J, Tomoda T, et al:
Clinical and immunologic evaluation of dendritic cell-based
immunotherapy in combination with gemcitabine and/or S-1 in
patients with advanced pancreatic carcinoma. Pancreas. 41:195–205.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Campbell AC, Hersey P, MacLennan IC, Kay
HE and Pike MC: Immunosuppressive consequences of radiotherapy and
chemotherapy in patients with acute lymphoblastic leukaemia. Br Med
J. 2:385–388. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Harris J, Sengar D, Stewart T and Hyslop
D: The effect of immunosuppressive chemotherapy on immune function
in patients with malignant disease. Cancer. 37(2 Suppl): 1058–1069.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sugiyama H: Cancer immunotherapy targeting
Wilms’ tumor gene WT1 product. Expert Rev Vaccines. 4:503–512.
2005.
|
|
19.
|
Mukherjee P, Ginardi AR, Madsen CS,
Sterner CS, Adriance MC, Tevethia MJ and Gendler SJ: Mice with
spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs
that eradicate tumors when adoptively transferred. J Immunol.
165:3451–3460. 2000. View Article : Google Scholar
|
|
20.
|
Cheever MA, Allison JP, Ferris AS, et al:
The prioritization of cancer antigens: a national cancer institute
pilot project for the acceleration of translational research. Clin
Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Okamoto M, Furuichi S, Nishioka Y, et al:
Expression of toll-like receptor 4 on dendritic cells is
significant for anti-cancer effect of dendritic cell-based
immunotherapy in combination with an active component of OK-432, a
streptococcal preparation. Cancer Res. 64:5461–5470. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Okamoto M, Oshikawa T, Tano T, et al:
Involvement of Toll-like receptor 4 signaling in interferon-gamma
production and antitumor effect by a streptococcal agent OK-432. J
Natl Cancer Inst. 95:316–326. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Okamoto M, Oshikawa T, Tano T, et al:
Mechanism of anti-cancer host response induced by OK-432, a
streptococcal preparation, mediated by phagocytosis and Toll-like
receptor 4 signaling. J Immunother. 29:78–86. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Oshikawa T, Okamoto M, Tano T, et al:
Anti-tumor effect of OK-432-derived DNA: one of the active
constituents of OK-432, a streptococcal immunotherapeutic agent. J
Immunother. 29:143–150. 2006.PubMed/NCBI
|
|
25.
|
Nakahara S, Tsunoda T, Baba T, et al:
Dendritic cells stimulated with a bacterial product, OK-432,
efficiently induce cytotoxic T lymphocytes specific to tumor
rejection peptide. Cancer Res. 63:4112–4118. 2003.PubMed/NCBI
|
|
26.
|
Itoh T, Ueda Y, Okugawa K, et al:
Streptococcal preparation OK432 promotes functional maturation of
human monocyte-derived dendritic cells. Cancer Immunol Immunother.
52:207–214. 2003.PubMed/NCBI
|
|
27.
|
Sato M, Takayama T, Tanaka H, et al:
Generation of mature dendritic cells fully capable of T helper type
1 polarization using OK-432 combined with prostaglandin E(2).
Cancer Sci. 94:1091–1098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Larbouret C, Robert B, Navarro-Teulon I,
et al: In vivo therapeutic synergism of anti-epidermal growth
factor receptor and anti-HER2 monoclonal antibodies against
pancreatic carcinomas. Clin Cancer Res. 13:3356–3362. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nair SK, Hull S, Coleman D, Gilboa E,
Lyerly HK and Morse MA: Induction of carcinoembryonic antigen
(CEA)-specific cytotoxic T-lymphocyte responses in vitro using
autologous dendritic cells loaded with CEA peptide or CEA RNA in
patients with meta-static malignancies expressing CEA. Int J
Cancer. 82:121–124. 1999. View Article : Google Scholar
|
|
30.
|
Kontani K, Taguchi O, Ozaki Y, et al:
Novel vaccination protocol consisting of injecting MUC1 DNA and
nonprimed dendritic cells at the same region greatly enhanced
MUC1-specific antitumor immunity in a murine model. Cancer Gene
Ther. 9:330–337. 2002. View Article : Google Scholar
|
|
31.
|
Cannon MJ, Santin AD and O’Brien TJ:
Immunological treatment of ovarian cancer. Curr Opin Obstet
Gynecol. 16:87–92. 2004. View Article : Google Scholar
|
|
32.
|
Nagayama H, Sato K, Morishita M, et al:
Results of a phase I clinical study using autologous tumour
lysate-pulsed monocyte-derived mature dendritic cell vaccinations
for stage IV malignant melanoma patients combined with low dose
interleukin-2. Melanoma Res. 13:521–530. 2003. View Article : Google Scholar
|
|
33.
|
Sugie C, Shibamoto Y, Ayakawa S, et al:
Craniospinal irradiation using helical tomotherapy: evaluation of
acute toxicity and dose distribution. Technol Cancer Res Treat.
10:187–195. 2011.PubMed/NCBI
|
|
34.
|
Shibamoto Y, Naruse A, Fukuma H, Ayakawa
S, Sugie C and Tomita N: Influence of contrast materials on dose
calculation in radiotherapy planning using computed tomography for
tumors at various anatomical regions: a prospective study.
Radiother Oncol. 84:52–55. 2007. View Article : Google Scholar
|
|
35.
|
Iwata H, Shibamoto Y, Hashizume C, et al:
Hypofractionated stereotactic body radiotherapy for primary and
metastatic liver tumors using the Novalis image-guided system:
preliminary results regarding efficacy and toxicity. Technol Cancer
Res Treat. 9:619–627. 2010. View Article : Google Scholar
|
|
36.
|
Shibamoto Y, Hashizume C, Baba F, et al:
Stereotactic body radiotherapy using a radiobiology-based regimen
for stage I nonsmall cell lung cancer: a multicenter study. Cancer.
118:2078–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Reits EA, Hodge JW, Herberts CA, et al:
Radiation modulates the peptide repertoire, enhances MHC class I
expression, and induces successful antitumor immunotherapy. J Exp
Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Suzuki Y, Mimura K, Yoshimoto Y, et al:
Immunogenic tumor cell death induced by chemoradiotherapy in
patients with esophageal squamous cell carcinoma. Cancer Res.
72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Finkelstein SE, Rodriguez F, Dunn M, et
al: Serial assessment of lymphocytes and apoptosis in the prostate
during coordinated intraprostatic dendritic cell injection and
radiotherapy. Immunotherapy. 4:373–382. 2012. View Article : Google Scholar
|
|
40.
|
Finkelstein SE, Iclozan C, Bui MM, et al:
Combination of external beam radiation (EBRT) with intratumoral
injection of dendritic cells as neo-adjuvant treatment of high-risk
soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys.
82:924–932. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Nikitina EY and Gabrilovich DI:
Combination of gamma-irradiation and dendritic cell administration
induces a potent antitumor response in tumor-bearing mice: approach
to treatment of advanced stage cancer. Int J Cancer. 94:825–833.
2001. View Article : Google Scholar
|
|
42.
|
Gupta A, Probst HC, Vuong V, et al:
Radiotherapy promotes tumor-specific effector CD8+T
cells via dendritic cell activation. J Immunol. 189:558–566. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Sharma A, Bode B, Wenger RH, et al:
γ-Radiation promotes immunological recognition of cancer cells
through increased expression of cancer-testis antigens in vitro and
in vivo. PLoS One. 6:e282172012.
|
|
44.
|
Postow MA, Callahan MK, Barker CA, et al:
Immunologic correlates of the abscopal effect in a patient with
melanoma. N Eng J Med. 366:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Keilholz U, Weber J, Finke JH, et al:
Immunologic monitoring of cancer vaccine therapy: results of a
workshop sponsored by the Society for Biological Therapy. J
Immunother. 25:97–138. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Suzuki E, Sun J, Kapoor V, Jassar AS and
Albelda SM: Gemcitabine has significant immunomodulatory activity
in murine tumor models independent of its cytotoxic effects. Cancer
Biol Ther. 6:880–885. 2007. View Article : Google Scholar : PubMed/NCBI
|
